Related Experiment Video
Updated: Sep 15, 2025
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
DTI-ALPS index-assessed glymphatic dysfunction mediates Alzheimer's cognitive decline via amyloid-β-dependent
Yan Zhang1, Gan Huang1, Jieli Geng2
1Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Purpose:
The role of glymphatic dysfunction in Alzheimer's disease (AD), as measured by diffusion tensor imaging along perivascular spaces (DTI-ALPS) indexing of perivascular function, its progression, and its interaction with amyloid-β (Aβ) and tau proteins, remains controversial. To investigate whether the DTI-ALPS index mediates AD-related cognitive decline through Aβ/tau-dependent pathways using tri-tracer PET/MRI.
Methods:
This retrospective study (2021-2024) analyzed 140 participants (median age 69.00 [61.00, 74.00] years; 84 women), including 99 with AD (37 early-onset [EOAD], 62 late-onset [LOAD]), 35 with mild cognitive impairment (MCI), and 6 with subjective cognitive decline (SCD). All participants underwent simultaneous [1⁸F] Florbetapir (Aβ), [1⁸F] PI-2620(tau), and [1⁸F] FDG PET/MRI with DTI-ALPS indexing for glymphatic function quantification. Causal mediation analysis was used to assess the relationships between biomarkers (P < 0.05).
Results:
The ALPS index progressively decreased across clinical stages (SCD: 1.51 ± 0.08 vs. MCI: 1.37 ± 0.13 vs. AD: 1.32 ± 0.14; P = 0.001), correlating with higher Aβ-PET (r = - 0.31, P < 0.001), tau-PET (ρ = - 0.18, P = 0.035), and FDG-PET scores (ρ = - 0.22, P = 0.008). Aβ-PET fully mediated the ALPS effects on FDG-PET (β = - 0.14, P = 0.002) and cognition (β = 0.12 ~ 0.14, P < 0.01), independent of tau (P > 0.05). The Aβ-negative subgroups showed correlations with ALPS-age (r = - 0.48, P = 0.007), ALPS-education (r = 0.39, P = 0.035), and ALPS-cognition (MoCA: r = 0.62, P < 0.001). The Aβ-positive subgroups revealed inverse ALPS-Aβ associations (ρ = - 0.27, P = 0.010; age/education-adjusted ρ = - 0.24, P = 0.022) alongside positive adjusted correlations with cognition (MMSE: ρ = 0.28, P = 0.009). EOAD exhibited distinct ALPS-cognition relationships compared to LOAD (MMSE: r = - 0.39, P = 0.016 vs. ρ = - 0.06, P = 0.620).
Conclusion:
DTI-ALPS quantifies glymphatic dysfunction driving AD progression predominantly through Aβ-dependent pathways, with EOAD demonstrating distinct neuroimaging-cognition relationships compared to LOAD.
Insights
Glymphatic dysfunction, measured by diffusion tensor imaging along perivascular spaces (DTI-ALPS), drives Alzheimer's disease progression primarily via amyloid-beta pathways. Early-onset AD shows unique neuroimaging-cognition links compared to late-onset AD.
Area of Science:
- Neuroimaging and Neurodegeneration
- Glymphatic System Function
- Alzheimer's Disease Pathophysiology
Background:
- Glymphatic dysfunction is implicated in Alzheimer's disease (AD) progression.
- Diffusion tensor imaging along perivascular spaces (DTI-ALPS) quantifies perivascular function.
- The interplay between glymphatic function, amyloid-beta (Aβ), and tau in AD is not fully understood.
Purpose of the Study:
- To investigate if DTI-ALPS index mediates AD-related cognitive decline.
- To explore the role of Aβ and tau pathways in this mediation.
- To utilize simultaneous tri-tracer PET/MRI for comprehensive biomarker analysis.
Main Methods:
- Retrospective analysis of 140 participants (AD, MCI, SCD) aged 61-74.
- Simultaneous [18F]Florbetapir (Aβ), [18F]PI-2620 (tau), and [18F]FDG PET/MRI with DTI-ALPS.
- Causal mediation analysis to assess biomarker relationships (P < 0.05).
Main Results:
- The ALPS index decreased progressively across clinical stages (SCD > MCI > AD).
- Lower ALPS correlated with higher Aβ-PET, tau-PET, and lower FDG-PET.
- Aβ-PET fully mediated the effects of ALPS on cognition and brain metabolism, independent of tau.
- Early-onset AD (EOAD) showed distinct ALPS-cognition relationships compared to late-onset AD (LOAD).
Conclusions:
- DTI-ALPS quantifies glymphatic dysfunction contributing to AD progression.
- The primary pathway involves Aβ-dependent mechanisms, influencing cognition and metabolism.
- Distinct neuroimaging-cognition relationships exist between EOAD and LOAD.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:22Alzheimer's Disease: Treatment